Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB248 alone or with pembrolizumab in advanced solid tumors
NCT05653882Phase 1Active, not recruiting
- Sponsor
- Asher Biotherapeutics
- Start
- Jan 2023
- Primary completion
- Aug 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of etakafusp alfa in solid tumor, non-small cell lung cancer (NSCLC), melanoma and 2 more (4 arms), sponsored by Asher Biotherapeutics. Primary endpoints: Frequency of Dose-Limiting Toxicities at Day 42, Frequency of Serious Adverse Events and 1 more. Started Jan 2023; status: active, not recruiting.
02
Drugs
etakafusp alfa
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)melanomahead and neck squamous cell carcinoma (HNSCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05653882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653882.